Health Canada to review AstraZeneca’s COVID-19 prevention drug – National |

AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.

If approved, it would be the first antibody protection of its kind in Canada.

Read more:
AstraZeneca COVID-19 drug prevents severe disease if given early, company says

The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.

AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.

Click to play video: 'Health Canada considers Merck’s experimental COVID-19 drug'

Health Canada considers Merck’s experimental COVID-19 drug

Health Canada considers Merck’s experimental COVID-19 drug – Oct 4, 2021

The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.

Story continues below advertisement

Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.

Read more:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug

© 2021 The Canadian Press

For all the latest health News Click Here 

Read original article here

Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.